N. Anthony Coles
From Wikipedia, the free encyclopedia
May 17, 1960
Harvard University (MPH)
Duke University (MD)
N. Anthony Coles | |
|---|---|
| Born | Neavelle Anthony Coles May 17, 1960 Roanoke, Virginia, U.S. |
| Education | Johns Hopkins University (BA) Harvard University (MPH) Duke University (MD) |
| Occupations | Physician, biotechnology executive |
| Spouse | Robyn Coles |
| Children | 3 |
Neavelle Anthony Coles (born May 17, 1960) is an American physician and biotechnology executive. He has served as chairman of the board of directors of Cerevel Therapeutics, a company focused on neurological disease treatments, since 2018, and was its chief executive officer from 2019 to 2023.[1][2]
Coles was born in Roanoke, Virginia, to Neavelle Anthony Coles, an accountant and minister, and Leona Rogers Coles, an office manager.[3] He graduated from DuVal High School in Lanham, Maryland.[4]
Coles earned a Bachelor of Arts from Johns Hopkins University, a Master of Public Health from Harvard University, and a Doctor of Medicine from Duke University.[1] He completed cardiology and internal medicine training at Massachusetts General Hospital and a research fellowship at Harvard Medical School.[5] In 2024, Duke University School of Medicine honored him with its Transformational Leadership Award.[6]
Career
Coles began his career in pharmaceuticals, holding executive roles at Merck & Co. (marketing ACE inhibitors), Bristol-Myers Squibb (senior vice president of strategy and policy, and marketing for neuroscience and infectious diseases), and Vertex Pharmaceuticals (senior vice president of commercial operations).[4][1]
From 2005 to 2008, Coles served as chief operating officer and president of NPS Pharmaceuticals, becoming chief executive officer in 2006.[7] He was president and CEO of Onyx Pharmaceuticals from 2008 to 2013, and chairman from 2012 to 2013, overseeing its $10.4 billion sale to Amgen in 2013.[1][8]
In 2014, Coles co-founded Yumanity Therapeutics with Susan Lindquist, serving as chairman and CEO until 2018, focusing on treatments for Alzheimer’s and Parkinson’s diseases.[8][3] Since 2013, he has been chairman and CEO of TRATE Enterprises, a private real estate and ventures company.[9]
At Cerevel Therapeutics, Coles served as CEO from 2019 to 2023, leading a $445 million public listing in 2020, and has been chairman since 2018.[2][1] He also serves on the board of directors of Regeneron Pharmaceuticals.[9] In 2021, he was elected to the American Academy of Arts and Sciences.[10]